AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Given Consensus Recommendation of “Strong Buy” by Analysts
Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus price target of $2.50 for the company and are expecting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given AVEO Pharmaceuticals an industry rank of 123 out of 265 based on the ratings given to its competitors.
AVEO has been the topic of a number of recent analyst reports. Zacks Investment Research raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. FBR & Co reaffirmed an “outperform” rating and set a $3.00 price target on shares of AVEO Pharmaceuticals in a research report on Monday, April 17th. ValuEngine downgraded AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Piper Jaffray Companies reaffirmed a “positive” rating on shares of AVEO Pharmaceuticals in a research report on Friday, June 23rd.
ILLEGAL ACTIVITY NOTICE: “AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Given Consensus Recommendation of “Strong Buy” by Analysts” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/07/17/aveo-pharmaceuticals-inc-nasdaqaveo-given-consensus-recommendation-of-strong-buy-by-analysts.html.
Several large investors have recently made changes to their positions in AVEO. NEA Management Company LLC raised its stake in shares of AVEO Pharmaceuticals by 57.9% in the first quarter. NEA Management Company LLC now owns 16,362,694 shares of the biopharmaceutical company’s stock worth $9,654,000 after buying an additional 6,000,000 shares during the period. Sphera Funds Management LTD. bought a new stake in shares of AVEO Pharmaceuticals during the first quarter worth $1,711,000. Perceptive Advisors LLC raised its stake in shares of AVEO Pharmaceuticals by 64.3% in the first quarter. Perceptive Advisors LLC now owns 5,108,808 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 2,000,000 shares during the period. Sabby Management LLC bought a new stake in shares of AVEO Pharmaceuticals during the first quarter worth $513,000. Finally, UBS Oconnor LLC bought a new stake in shares of AVEO Pharmaceuticals during the first quarter worth $291,000. 50.96% of the stock is currently owned by hedge funds and other institutional investors.
Shares of AVEO Pharmaceuticals (AVEO) opened at 2.66 on Monday. The firm’s 50-day moving average price is $0.89 and its 200 day moving average price is $0.73. AVEO Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $3.19. The stock’s market capitalization is $293.56 million.
AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of $2.53 million for the quarter. AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 728.85%. Analysts expect that AVEO Pharmaceuticals will post ($0.44) earnings per share for the current year.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.